u/greta_chukwu

Small correction: the trial was 23 weeks, not 36. Does not change your point but people will quote it.

link the wiki instead of retyping, but politely

Titration speed is a side-effect dial far more than an efficacy dial.

say which country and which plan type

the carve-out clause varies by employer

Strongly agree. ALT is where you catch the liver story early.

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

denial reason codes matter, ask for the actual code

Respectfully this is a sample of one presented as a finding.

sock puppet accounts ask the same leading questions

Week 23 checking in: nothing on the scale, no nausea, wondering if the pen is broken. No, it is just week 23.

Yeah, that is totally normal for week 23.

Adding to this: normal is doing more work than the comment implies.

I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.

Batch 8 appeared on BCH, QYB, and BCH claims it is raw material origin. Could be fine, could be reseller. Logged it in the directory.

group buy exit scams follow a pattern

Inter-lab variance on this kind of assay is routinely 1–2 points.

Disagree on that part. 98.1% and 98.3% on the same vial is normal.

Small correction: the trial was 6 weeks, not 4. Does not change your point but people will quote it.

Yeah, baseline matters more than any later number.

Ferritin tanked from 22 to 11. Small appetite, reduced iron intake, nobody was testing it until I asked.

A1c moves slowly, quarterly is plenty